Format

Send to

Choose Destination
J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007.

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.

Author information

1
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
2
Department of Biostatistics at HUP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
3
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: werth@mail.med.upenn.edu.
PMID:
24528907
PMCID:
PMC4333148
DOI:
10.1016/j.jaad.2013.11.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center